Dear Chair DeLauro and Ranking Member Granger
Dear Chair DeLauro and Ranking Member Granger, I write you as a concerned advocate for those with ALS (we lost Mom to ALS in 1997), a pers…
Related Articles
Novel Drug Made of Gold Nanocrystals Appears Safe in Multiple Sclerosis
Small study suggested benefits for MS patients with chronic optic neuropathy
How AI can help satisfy FDA’s drug, device diversity requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
Researchers set new standards for nanoparticles, helping patients with MS, ALS, Parkinson’s disease
Is it possible for nanoparticles to go through the digestive system and deliver medicine directly to the brain tissue? Researchers from Michigan State University say…
Battle against fatal neurodegenerative disease advances on two fronts
European researchers are pioneering a vaccine and treatment for amyotrophic lateral sclerosis.
Califf’s long day on Capitol Hill
Democrats and Republicans pressed FDA Commissioner Robert Califf on the FDA’s slow pace.
Enhanced Levels of Fractalkine and HSP60 in Cerebrospinal Fluid of Sporadic Amyotrophic Lateral Sclerosis Patients – PubMed
Amyotrophic Lateral Sclerosis (ALS) is a multifactorial neurodegenerative disorder with a significant contribution of non-cell autonomous mechanisms to motor neuronal degeneration. Amongst a plethora of…
Why an ALS Drug Was Pulled From the Market
Topline data show where sodium phenylbutyrate and taurursodiol fell short
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK, April 16,…
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited…
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
Private investments in public equities, or PIPEs, are all the rage in biotech, but some investors resent the sharing of nonpublic information.